A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of SUN13837 Injection in Adult Subjects With Acute Spinal Cord Injury
Phase of Trial: Phase II
Latest Information Update: 14 Aug 2017
Price : $35 *
At a glance
- Drugs SUN 13837 (Primary)
- Indications Spinal cord injuries
- Focus Therapeutic Use
- Sponsors Asubio Pharmaceuticals; Daiichi Sankyo Inc
- 01 Jul 2015 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
- 14 Oct 2014 Status changed from recruiting to active, no longer recruiting, according to the ClinicalTrials.gov record.
- 13 Oct 2014 The trial status is given as completed in UKCRN,and as recruiting in NCT; retained as per NCT because it includes more locations than UKCRN.